

## RUBRA MEDICAMENTS LIMITED

### Statement of Standalone Unaudited Financial Results for the quarter ended June 30, 2020

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Figures for the previous year ended
		30-Jun-2020	31-Mar-2020	30-Jun-2019	31-Mar-2020
		Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	0.00	63.00	9.26	98.76
II	Other Income	0.00	0.00	0.00	0.00
III	<b>Total Income (I + II)</b>	<b>-</b>	<b>63.00</b>	<b>9.26</b>	<b>98.76</b>
IV	<b>Expenses:</b>				
	Cost of Materials Consumed	0.00	0.00	0.00	0.00
	Purchases of Stock in Trade	0.00	0.00	0.00	14.68
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00
	Employee benefits Expense	0.60	1.83	6.55	13.06
	Finance Costs	0.00	0.00	0.09	0.12
	Depreciation & amortisation expense	0.00	0.04	0.05	0.17
	Other Expenses	0.00	63.33	1.42	69.16
	<b>Total Expenses (IV)</b>	<b>0.60</b>	<b>65.20</b>	<b>8.11</b>	<b>97.19</b>
V	<b>Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>-0.60</b>	<b>-2.20</b>	<b>1.15</b>	<b>1.57</b>
VI	Exceptional Items	0.00	3.06	0.00	3.06
VII	<b>Profit / (loss) before tax (V-VI)</b>	<b>-0.60</b>	<b>0.86</b>	<b>1.15</b>	<b>4.63</b>
VIII	Tax Expense:				
	(1) Current tax	0.00	1.45	0.00	1.45
	(2) Deferred tax	0.00	0.03	0.00	0.03
IX	<b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>-0.60</b>	<b>-0.62</b>	<b>1.15</b>	<b>3.15</b>
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00
XII	<b>Profit/(loss) from Discontinuing operations (after tax)(X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIII	<b>Profit / (Loss) for the period (IX+XII)</b>	<b>-0.60</b>	<b>-0.62</b>	<b>1.15</b>	<b>3.15</b>
XIV	Other comprehensive income				
	A (i) Items that will not be reclassified to profit or loss				
	(ii) Income tax relating to items that will not be reclassified to profit or loss				
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit or loss				
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	-0.60	-0.62	1.15	3.15
XVI	Earnings per equity share (for continuing operation):				
	(1) Basic	0.00	0.00	0.02	0.06
	(2) Diluted	0.00	0.00	0.02	0.06
XVII	Earnings per equity share (for discontinued operation):				
	(1) Basic				
	(2) Diluted	0.00	0.00	0.00	0.06
XVIII	Earnings per equity share (for discontinued & continuing operation):				
	(1) Basic	0.00	0.00	0.02	0.06
	(2) Diluted	0.00	0.00	0.02	0.06
1	<b>NOTES:</b>				
2	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.				
3	The Segment - wise details are not applicable to the Company as the Company has no segments.				
4	The results are Ind-AS compliant however, the previous year figures are not subject to limit review or audit. However the management has exercised necessary due - diligence to ensure that the Financial Results provide a true and fair view of its affairs.				
4	The result is provisional and unaudited and subject to change, regrouping and restatement.				

For Rubra Medicaments Limited

Place: Mumbai  
Date:- August 31, 2020

Abha Kapoor  
Director (Finance) & CFO  
DIN: 02799429